239 related articles for article (PubMed ID: 16413220)
1. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.
Sandra F; Hendarmin L; Nakamura S
Oral Oncol; 2006 Apr; 42(4):415-20. PubMed ID: 16413220
[TBL] [Abstract][Full Text] [Related]
2. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
3. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
[TBL] [Abstract][Full Text] [Related]
5. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
Chamoux E; Houde N; L'Eriger K; Roux S
J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379
[TBL] [Abstract][Full Text] [Related]
7. Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL).
Vishvanath A; Itinteang T; Tan ST; Day DJ
Histopathology; 2011 Sep; 59(3):397-406. PubMed ID: 22034880
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of bone remodeling molecules expression in different types of jaw ameloblastoma.
Iakovou M; Chrysomali E; Piperi E; Fanourakis G; Sklavounou A; Vlachodimitropoulos D; Tseleni-Balafouta S
J Oral Pathol Med; 2015 Aug; 44(7):543-51. PubMed ID: 25243582
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?
Holen I; Cross SS; Neville-Webbe HL; Cross NA; Balasubramanian SP; Croucher PI; Evans CA; Lippitt JM; Coleman RE; Eaton CL
Breast Cancer Res Treat; 2005 Aug; 92(3):207-15. PubMed ID: 16155791
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin is expressed in colon carcinoma cells.
Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B
Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiological roles of osteoprotegerin (OPG).
Reid P; Holen I
Eur J Cell Biol; 2009 Jan; 88(1):1-17. PubMed ID: 18707795
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.
Rizzardi C; Leocata P; Ventura L; Zweyer M; Brollo A; Schneider M; Melato M
Anticancer Res; 2009 Apr; 29(4):1137-42. PubMed ID: 19414356
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.
McGonigle JS; Giachelli CM; Scatena M
Angiogenesis; 2009; 12(1):35-46. PubMed ID: 19105036
[TBL] [Abstract][Full Text] [Related]
14. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts.
da Silva TA; Batista AC; Mendonça EF; Leles CR; Fukada S; Cunha FQ
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Mar; 105(3):333-41. PubMed ID: 18061491
[TBL] [Abstract][Full Text] [Related]
15. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer.
De Toni EN; Thieme SE; Herbst A; Behrens A; Stieber P; Jung A; Blum H; Göke B; Kolligs FT
Clin Cancer Res; 2008 Aug; 14(15):4713-8. PubMed ID: 18676739
[TBL] [Abstract][Full Text] [Related]
16. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
[TBL] [Abstract][Full Text] [Related]
17. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
[TBL] [Abstract][Full Text] [Related]
18. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease.
Reenaers C; Franchimont N; Oury C; Belaiche J; Malaise M; Bours V; Theatre E; Delvenne P; Louis E
Scand J Gastroenterol; 2008; 43(11):1334-45. PubMed ID: 18942021
[TBL] [Abstract][Full Text] [Related]
20. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
Théoleyre S; Kwan Tat S; Vusio P; Blanchard F; Gallagher J; Ricard-Blum S; Fortun Y; Padrines M; Rédini F; Heymann D
Biochem Biophys Res Commun; 2006 Aug; 347(2):460-7. PubMed ID: 16828054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
